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Introduction: Docetaxel, cisplatin plus 5-FU (DCF) regimen is a use-
ful chemotherapy against malignant diseases such as advanced head 
and neck cancer. However, DCF regimen is sometimes withdrawn by 
severe myelosuppression and nonhematologic toxic effects, includ-
ing mucositis. Previous animal and clinical studies showed that the 
degrees of docetaxel-, cisplatin-, and 5-FU–induced toxicities depend 
on their dosing time. We have reported that the frequency of doc-
etaxel-induced intestinal mucositis was greater after dosing at an 
active phase than at an inactive phase in mice. The aim of the present 
study was to determine the influence of dosing schedule of DCF regi-
men on chemotherapy-induced toxicities in clinical practice.
Patients (or Materials) and Methods: Patients with oral squamous 
cell carcinoma treated with DCF regimen were randomly allocated 
to the following 2 groups: chemotherapy started from morning 
(10:30) in the first group and evening (18:30) in the second group. 
Hematologic and nonhematologic adverse effects were assessed for 
14 days after the start of chemotherapy.
Results: The most frequently observed mild to severe adverse effects 
were neutropenia, diarrhea, stomatitis, and nausea. The frequency 
of grade 3 to 4 neutropenia was 62.5% (5 of 8) in the morning 
group and 28.6% (2 of 7) in the evening group. Grade 3 to 4 event 
of stomatitis and grade 3 event of nausea were more detected in the 
morning group.
Conclusion: These findings suggest that chronotherapy of DCF 
regimen might diminish severe adverse effects in patients with oral 
squamous cell carcinoma.
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Introduction: This pilot study, within the ARITMO project, evalu-
ated the population exposure to antipsychotics (APs: ATC group 
N05A, excluding lithium) with proarrhythmic risk, by analyzing the 
FDA Database (FDA_AERS) and European drug utilization data (12 
countries).
Patients (or Materials) and Methods: Cases of QT prolongation and 
torsades de pointes (TdP) associated with APs were retrieved from 
the FDA_AERS (2004–2011) database. APs with unexpected signals 
were defined by disproportionality (Reporting Odds Ratio [ROR], 
with 95% CI > 1, cases > 3) and checking in Arizona_CERT (www.
azcert.org). Consumption data (2006–2010) were provided from 
administrative databases from 12 European countries. Data were 
expressed as DDDs/TID (defined daily doses per thousand inhabit-
ants per day).
Results: Thirty-one APs were reported in 1467 cases of TdP/QT 
prolongation, with 10 unexpected signals: amisulpride (ROR = 25.0; 
95%CI, 17.6–35.6), aripiprazole (1.7; 1.3–2.2), bromperidol (88.4; 
37.7–207.9), chlorprothixene (10.7; 3.9–29.0), cyamemazine (7.6; 
4.3–13.5), fluphenazine (7.9; 3.9–16.0), levomepromazine (5.2; 2.3–
11.6), olanzapine (4.7; 4.1–5.3), prothipendyl (21.0; 10.7–41.4), and 
zuclopenthixol (14.9; 6.9–31.8). In all countries, AP use increased 
over 5 years from only +0.35 DDD/TID (Norway) to +11.01 (Serbia, 
preliminary data). The atypical/typical ratio increased in line with 
expectations. There was variable AP utilization in 2010, from 5.04 
(Estonia) to 16.57 (Serbia, preliminary data). The mean use of 
APs with unexpected signals ranged from 1.72 (Estonia) to 5.45 
(Slovenia). Olanzapine was stable but widely used and peaked at 
2.9 in Norway. Aripiprazole utilization generally increased. There 
appeared to be substantial utilization of fluphenazine in Serbia (3.77 
in 2010) and cyamemazine in France (2.81 in 2009).
Conclusion: Different exposure to AP use among countries implies 
different levels of population risk. The use of atypical APs is growing 
(eg, aripiprazole). Olanzapine should be monitored by regulators, 
due to its appreciable utilization in most countries. Fluphenazine 
and cyamemazine are specific concerns in Serbia and France, respec-
tively. The study also demonstrates the synergy between drug utili-
zation and adverse event databases to alert health policy personnel 
of potential future activities to reduce ADRs, especially from drugs 
with unexpected signals. As a result, help promote higher standards 
of prescribing in the future.
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Introduction: We report a case of digoxin intoxication with severe 
visual symptoms.
Patients (or Materials) and Methods: Digoxin 0.25 mg QD for atrial 
fibrillation was prescribed to a 91-year-old woman with an estimated 
creatinine clearance of 18 mL/min. Within 2 to 3 weeks, she devel-
oped nausea, vomiting, and dysphagia, and began complaining of 
snowy and blurry vision, photopsia, dyschromatopsia, aggravated 
bedtime visual and proprioceptive illusions (she felt as being on a 
boat), and colored hallucinations. She consulted her family doctor 
twice and visited the eye clinic once until, 1 month after starting 
digoxin, impaired autonomy led her to be admitted to the emergency 
department.
Results: Digoxin intoxication was confirmed by a high plasma level 
measured on admission (5.7 µg/L; reference range, 0.8-2 µg/L). After 
stopping digoxin, general symptoms resolved in a few days, but 
visual symptoms persisted. Ophtalmologic care and follow-up diag-
nosed digoxin intoxication superimposed on pre-existing left eye 
(LE) cataract, dry age-related macular degeneration (DMLA), and 
Charles Bonnet syndrome. Visual acuity was 0.4 (right eye, RE) 
and 0.5 (LE). Ocular fundus was physiologic except for bilateral 
